CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.

Neurology · 2014 · PMC4240428 · PMID 25239835

Europe PMC DOI

hedged sentence

0.0534

closest p · 1.1× alpha

0.0534

boldest claim

The sentences

a clear trendp = 0.0534so close (0.05 < p ≤ 0.1)

The cumulative T1 Gd lesion volume for weeks 4, 8, and 12 (secondary outcome measure) was lower in the ATL1102 group than the placebo group: 358 (1,028.4) mm3 vs 589 (1,107.6) mm3, with a clear trend towards significance (1-sided p = 0.0534) (90% CI −0.129, 12.863).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.